[{"id":"cd6bbcee-c7e4-4f63-a4d9-478a5b04000b","acronym":"","url":"https://clinicaltrials.gov/study/NCT06136988","created_at":"2023-11-19T12:16:11.097Z","updated_at":"2024-07-02T16:35:28.828Z","phase":"Phase 1/2","brief_title":"A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma.","source_id_and_acronym":"NCT06136988","lead_sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • paclitaxel • Enshuxing (enlonstobart) • albumin-bound docetaxel (CPO100)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 129","initiation":"Initiation: 12/01/2023","start_date":" 12/01/2023","primary_txt":" Primary completion: 04/01/2027","primary_completion_date":" 04/01/2027","study_txt":" Completion: 04/01/2028","study_completion_date":" 04/01/2028","last_update_posted":"2023-11-18"},{"id":"84ae37b2-6f5c-4e7e-be94-a941521ec5e5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05863325","created_at":"2023-05-18T14:04:44.124Z","updated_at":"2024-07-02T16:35:30.313Z","phase":"Phase 2","brief_title":"A Study to Compare the Efficacy and Safety of HB1801 to Taxotere in Advanced Non-Small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT05863325","lead_sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","biomarkers":" EGFR • ALK • ROS1","pipe":" | ","alterations":" EGFR mutation • ALK fusion • ROS1 fusion • ALK-ROS1 fusion","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK fusion • ROS1 fusion • ALK-ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • albumin-bound docetaxel (CPO100)"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 06/27/2023","start_date":" 06/27/2023","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2023-11-06"},{"id":"f63fc555-27f3-4ad1-bc4b-ca48a145c8a4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05027204","created_at":"2021-08-30T21:53:04.885Z","updated_at":"2024-07-02T16:36:02.491Z","phase":"Phase 1/2","brief_title":"A Study of Docetaxel for Injection (Albumin-bound) in Combination With Nivolumab in Patients With Head and Neck (SCCHN)","source_id_and_acronym":"NCT05027204","lead_sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • docetaxel • albumin-bound docetaxel (CPO100)"],"overall_status":"Recruiting","enrollment":" Enrollment 94","initiation":"Initiation: 03/04/2022","start_date":" 03/04/2022","primary_txt":" Primary completion: 10/31/2023","primary_completion_date":" 10/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2022-10-13"}]